JP2008508353A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508353A5
JP2008508353A5 JP2007524768A JP2007524768A JP2008508353A5 JP 2008508353 A5 JP2008508353 A5 JP 2008508353A5 JP 2007524768 A JP2007524768 A JP 2007524768A JP 2007524768 A JP2007524768 A JP 2007524768A JP 2008508353 A5 JP2008508353 A5 JP 2008508353A5
Authority
JP
Japan
Prior art keywords
benzo
dihydro
phenyl
tetrahydro
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007524768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508353A (ja
Filing date
Publication date
Priority claimed from SE0401971A external-priority patent/SE0401971D0/xx
Application filed filed Critical
Publication of JP2008508353A publication Critical patent/JP2008508353A/ja
Publication of JP2008508353A5 publication Critical patent/JP2008508353A5/ja
Abandoned legal-status Critical Current

Links

JP2007524768A 2004-08-02 2005-07-27 ヒスタミンh3受容体リガンドとしてのピペリジン誘導体 Abandoned JP2008508353A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401971A SE0401971D0 (sv) 2004-08-02 2004-08-02 Piperidne derivatives
PCT/SE2005/001189 WO2006014136A1 (en) 2004-08-02 2005-07-27 Piperidine derivatives as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
JP2008508353A JP2008508353A (ja) 2008-03-21
JP2008508353A5 true JP2008508353A5 (enExample) 2009-03-12

Family

ID=32906883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007524768A Abandoned JP2008508353A (ja) 2004-08-02 2005-07-27 ヒスタミンh3受容体リガンドとしてのピペリジン誘導体

Country Status (14)

Country Link
US (1) US20080064706A1 (enExample)
EP (1) EP1781613A1 (enExample)
JP (1) JP2008508353A (enExample)
KR (1) KR20070043998A (enExample)
CN (1) CN1993325A (enExample)
AU (1) AU2005267932A1 (enExample)
BR (1) BRPI0514035A (enExample)
CA (1) CA2576112A1 (enExample)
IL (1) IL180548A0 (enExample)
MX (1) MX2007001226A (enExample)
RU (1) RU2007105970A (enExample)
SE (1) SE0401971D0 (enExample)
WO (1) WO2006014136A1 (enExample)
ZA (1) ZA200700683B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026844A1 (en) 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
EP1814875A4 (en) 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE
ES2639621T3 (es) 2004-12-30 2017-10-27 Janssen Pharmaceutica N.V. Derivados de fenilamida del ácido 4-(bencil)-piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (FAAH) para el tratamiento de la ansiedad, el dolor y otras afecciones
EP1909797A4 (en) 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
AU2008267895A1 (en) * 2007-06-22 2008-12-31 F. Hoffmann-La Roche Ag Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
US7888354B2 (en) 2007-11-13 2011-02-15 Taisho Pharmaceutical Co., Ltd Phenylpyrazole derivatives
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
AR088256A1 (es) 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
EP2789608A4 (en) 2011-12-08 2015-07-01 Taisho Pharmaceutical Co Ltd PHENYLPYRROLDERIVAT
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
TWI703130B (zh) 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
CA2949511A1 (en) * 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
EP3383853B1 (en) 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
KR102640774B1 (ko) 2016-03-22 2024-02-26 헬신 헬쓰케어 에스.에이. 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
US11077090B2 (en) 2016-07-29 2021-08-03 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
CN110678205B (zh) 2017-02-16 2023-05-23 桑诺维恩药品公司 治疗精神分裂症的方法
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc ISOCHROMANE COMPOUNDS AND THEIR USES
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
MY208662A (en) 2018-04-18 2025-05-22 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020086456A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
CN111349609A (zh) * 2018-12-21 2020-06-30 泰州医药城国科化物生物医药科技有限公司 一种无标记组胺受体h3的细胞筛选模型
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
EP3969444A4 (en) * 2019-05-13 2023-10-18 The Regents of the University of California COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
ES2819309B2 (es) * 2019-10-14 2021-11-17 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CN113549006B (zh) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
DE60234616D1 (de) * 2001-09-14 2010-01-14 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
US20060052597A1 (en) * 2002-10-22 2006-03-09 Best Desmond J Aryloxyalkylamine derivatives as h3 receptor ligands
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
EP1669350B1 (en) * 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives

Similar Documents

Publication Publication Date Title
JP2008508353A5 (enExample)
CN100418951C (zh) 环胺衍生物及其作为药物的用途
JP4753403B2 (ja) インテグリンのそのレセプターへの結合を阻害する化合物
ES2291464T3 (es) Derivados de n-(arilsulfonil)beta-aminoacidos que comprenden un grupo aminoetilo sustituido, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU2007105970A (ru) Пиперидиновые производные в качестве лигандов гистаминового из рецептора
ES2240339T3 (es) Derivados de oxibenzamidas en calidad de inhibidores de factor xa.
KR100927563B1 (ko) 방향족 화합물
JP5188814B2 (ja) 有機化合物
JP2008508352A5 (enExample)
JP2004520435A (ja) 新規非イミダゾール化合物
RU2003127723A (ru) Ацилированные 6, 7, 8, 9 - тетрагидо - 5h - бензоциклогептениламины и их применение в качестве фармацевтических препаратов
US7615642B2 (en) Therapeutic compounds
US20070249618A1 (en) Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression
SK10102003A3 (sk) Acylované indanylamíny, farmaceutická kompozícia s ich obsahom, spôsob syntézy a ich použitie ako liečivá
PT2207773E (pt) Composto heterocíclico e composição farmacêutica que contém o mencionado composto
JPWO2006057270A1 (ja) 含窒素3環化合物
JPWO2004101514A1 (ja) シアノフルオロピロリジン誘導体
ES2286474T3 (es) Derivados de 4-(finilpiperazinilmetil) benzamida y su uso para el tratamiento de dolor o transtornos gastrointestinales.
WO2006125621A1 (en) Substituted piperidines as renin inhibitors
CN102548985A (zh) 取代羰基化合物
SK286687B6 (sk) Sulfónamidy, spôsob ich výroby, medziprodukty, liečivo a farmaceutická kompozícia s ich obsahom
SK13912003A3 (sk) 4-(Fenyl(piperidin-4-yl)amino)benzamidové deriváty a ich požitie na liečbu bolesti, anxiety alebo gastrointestinálnych porúch
ES2285179T3 (es) Derivados de fenil-piperidin-4-ilidene-metil-benzamida para el tratamiento de dolor o trastornos gastrointestinales.
JPWO2005030722A1 (ja) N−置換−n−(4−ピペリジニル)アミド誘導体
CN115667227B (zh) 基质金属蛋白酶(mmp)抑制剂及其使用方法